Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 22, 2014, 122 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $90.00 to $13,547,000.00.

Highlighted Stocks Traded by Insiders:

Eli Lilly and (LLY) - FREE Research Report

Lilly Endowment Inc, who is 10% Owner at Eli Lilly and, sold 230,000 shares at $58.90 on May 22, 2014. Following this transaction, the 10% Owner owned 134.7 million shares meaning that the stake was reduced by 0.17% with the 230,000-share transaction.

The shares most recently traded at $59.73, up $0.83, or 1.39% since the insider transaction. Historical insider transactions for Eli Lilly and go as follows:

  • 4-Week # shares bought: 17,157
  • 4-Week # shares sold: 750,000
  • 12-Week # shares bought: 17,157
  • 12-Week # shares sold: 750,000
  • 24-Week # shares bought: 29,588
  • 24-Week # shares sold: 769,648

The average volume for Eli Lilly and has been 5.1 million shares per day over the past 30 days. Eli Lilly and has a market cap of $66.1 billion and is part of the health care sector and drugs industry. Shares are up 17.1% year-to-date as of the close of trading on Thursday.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. The stock currently has a dividend yield of 3.32%. The company has a P/E ratio of 16.5. Currently, there are 5 analysts who rate Eli Lilly and a buy, 2 analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LLY - FREE

TheStreet Quant Ratings

rates Eli Lilly and as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Eli Lilly and Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Imperva (IMPV) - FREE Research Report

Kraynak Mark E., who is Senior VP, Worldwide Marketing at Imperva, sold 644 shares at $21.63 on May 22, 2014. Following this transaction, the Senior VP, Worldwide Marketing owned 17,851 shares meaning that the stake was reduced by 3.48% with the 644-share transaction.

The shares most recently traded at $20.98, down $0.65, or 3.1% since the insider transaction. Historical insider transactions for Imperva go as follows:

  • 4-Week # shares sold: 644
  • 12-Week # shares sold: 644
  • 24-Week # shares sold: 644

The average volume for Imperva has been 699,400 shares per day over the past 30 days. Imperva has a market cap of $553.1 million and is part of the technology sector and computer software & services industry. Shares are down 55.91% year-to-date as of the close of trading on Thursday.

Imperva, Inc. develops, markets, sells, services, and supports data center security solutions that protect high value applications and data assets in physical and virtual data centers. The company operates in two segments, Imperva and Incapsula. Currently, there are 6 analysts who rate Imperva a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IMPV - FREE

TheStreet Quant Ratings

rates Imperva as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Imperva Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Office Depot (ODP) - FREE Research Report

Garcia C Elisa D, who is EVP-Chief Legal Officer & Secy at Office Depot, sold 22,097 shares at $5.01 on May 22, 2014. Following this transaction, the EVP-Chief Legal Officer & Secy owned 412,043 shares meaning that the stake was reduced by 5.09% with the 22,097-share transaction.

The shares most recently traded at $5.02, up $0.01, or 0.2% since the insider transaction. Historical insider transactions for Office Depot go as follows:

  • 4-Week # shares bought: 15,000
  • 4-Week # shares sold: 9,488
  • 12-Week # shares bought: 81,870
  • 12-Week # shares sold: 42,465
  • 24-Week # shares bought: 81,870
  • 24-Week # shares sold: 152,402

The average volume for Office Depot has been 10.9 million shares per day over the past 30 days. Office Depot has a market cap of $2.7 billion and is part of the services sector and specialty retail industry. Shares are down 4.73% year-to-date as of the close of trading on Thursday.

Office Depot, Inc., together with its subsidiaries, supplies office products and services. Currently, there are 4 analysts who rate Office Depot a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ODP - FREE

TheStreet Quant Ratings

rates Office Depot as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and poor profit margins. Get the full

Office Depot Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null